{
    "clinical_study": {
        "@rank": "144559", 
        "arm_group": [
            {
                "arm_group_label": "Group Mg", 
                "arm_group_type": "Experimental", 
                "description": "Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1  + sugammadex 2 mg.kg-1"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Active Comparator", 
                "description": "Saline 100 ml  + rocuronium 0.6 mg.kg-1  + sugammadex 2 mg.kg-1"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to determine the recovery time of moderate neuromuscular blockade\n      with sugammadex in adults pretreated with magnesium sulfate."
        }, 
        "brief_title": "Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuromuscular Blockade", 
        "detailed_description": {
            "textblock": "Sugammadex is a novel neuromuscular blocking reversal agent. Its mechanism of action is the\n      encapsulation of rocuronium and vecuronium molecules. Numerous studies show a potential role\n      of magnesium in reducing anesthetic requirements, sympathetic response to surgical trauma,\n      antinociceptive action and neuroprotective effects. However, its use is limited because\n      magnesium potentiates non-depolarizing neuromuscular blocking agents.\n\n      Primary outcome: evaluate the effect of pretreatment with magnesium sulfate on the time\n      reversal with sugammadex (recovery of the T4/T1 ratio = 0.9) of moderate neuromuscular\n      blockade (two answers to a train-of-four TOF) induced by rocuronium.\n\n      Secondary outcome: evaluate severe respiratory events, the incidence of residual\n      neuromuscular blockade in the post anesthesia recovery room and postoperative pain."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-65 years\n\n          -  ASA physical status 1 or 2\n\n          -  weight BMI 18.5-24.9\n\n          -  otorhinolaryngological surgeries\n\n        Exclusion Criteria:\n\n          -  major surgery associated with massive blood loss or fluid replacement\n\n          -  any known allergy to magnesium sulphate or any other study drugs\n\n          -  pregnant\n\n          -  anatomical malformations expected to result in a difficult intubation;\n\n          -  known or suspected neuromuscular disorders and/or significant hepatic or renal\n             dysfunction\n\n          -  administration of any medication known to interfere with neuromuscular blocking\n             agents (such as anticonvulsants, aminoglycosides, calcium channel blockers and\n             magnesium containing medications)\n\n          -  hypomagnesemia, hypermagnesemia, hypocalcemia, hypercalcemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828385", 
            "org_study_id": "PAGF-01M"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group Mg", 
                "description": "Magnesium sulfate + rocuronium + sugammadex", 
                "intervention_name": "Magnesium Sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group C", 
                "description": "Saline + rocuronium + sugammadex", 
                "intervention_name": "Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Magnesium Sulfate", 
                "Rocuronium", 
                "Molecular Mechanisms of Pharmacological Action", 
                "Physiological Effects of Drugs"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Physiological Effects of Drugs", 
            "Rocuronium", 
            "Sugammadex sodium", 
            "Magnesium", 
            "Molecular Mechanisms of Pharmacological Action", 
            "Neuromuscular block, antagonism", 
            "Pharmacologic Actions"
        ], 
        "lastchanged_date": "April 9, 2013", 
        "location": {
            "contact": {
                "email": "pauloalipio1976@gmail.com", 
                "last_name": "Paulo A Germano Filho, MD", 
                "phone": "2187578888"
            }, 
            "contact_backup": {
                "email": "nubiavercosa@gmail.com", 
                "last_name": "N\u00fabia V Figueiredo, PhD", 
                "phone": "+5524916020"
            }, 
            "facility": {
                "address": {
                    "city": "Rio de Janeiro", 
                    "country": "Brazil", 
                    "state": "RJ", 
                    "zip": "21041-030"
                }, 
                "name": "Hospital Federal de Bonsucesso"
            }, 
            "investigator": [
                {
                    "last_name": "Paulo A Germano Filho, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Raphael C Rodrigues, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Vitor N Andrade, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ludmila B Henrique, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Luana Rodrigues, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Magnesium Sulfate on the Reversal of Neuromuscular Blockade With Sugammadex: a Prospective, Randomized Double-blind Trial", 
        "overall_contact": {
            "email": "pauloalipio1976@gmail.com", 
            "last_name": "Paulo A Germano Filho, MD", 
            "phone": "+552187578888"
        }, 
        "overall_contact_backup": {
            "email": "nubiavercosa@gmail.com", 
            "last_name": "N\u00fabia V Figueiredo, PhD", 
            "phone": "+552124916020"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Federal de Bonsucesso", 
                "last_name": "Paulo A Germano Filho, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universidade Federal do Rio de Janeiro", 
                "last_name": "N\u00fabia V Figueiredo, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Universidade Federal do Rio de Janeiro", 
                "last_name": "Ismar L Cavalcanti, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "When T1 reached 25%, a single bolus dose of sugammadex 2 mg.kg-1 was administered to facilitate the recovery.  The times to reach a TOF ratio of 0.9 and T1 height value were measured.", 
            "measure": "Recovery time of moderate neuromuscular blockade with sugammadex in adults pretreated with magnesium sulfate", 
            "safety_issue": "No", 
            "time_frame": "3 hours"
        }, 
        "reference": [
            {
                "PMID": "21364460", 
                "citation": "Herroeder S, Sch\u00f6nherr ME, De Hert SG, Hollmann MW. Magnesium--essentials for anesthesiologists. Anesthesiology. 2011 Apr;114(4):971-93. doi: 10.1097/ALN.0b013e318210483d. Review."
            }, 
            {
                "PMID": "21455074", 
                "citation": "Sauer M, Stahn A, Soltesz S, Noeldge-Schomburg G, Mencke T. The influence of residual neuromuscular block on the incidence of critical respiratory events. A randomised, prospective, placebo-controlled trial. Eur J Anaesthesiol. 2011 Dec;28(12):842-8. doi: 10.1097/EJA.0b013e328345cd11."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828385"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federal University of Rio de Janeiro", 
            "investigator_full_name": "Paulo Alipio Germano Filho", 
            "investigator_title": "MD, Post Graduate Student - master's degree", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Clinical tests and contraction of the adductor pollicis muscle in response to ulnar nerve train-of-four (TOF) stimulation was acceleromyographically quantified using a TOF-Watch SX.", 
            "measure": "Assess severe respiratory events, the incidence of residual neuromuscular blockade in anesthesia recovery room", 
            "safety_issue": "Yes", 
            "time_frame": "4 hours"
        }, 
        "source": "Universidade Federal do Rio de Janeiro", 
        "sponsors": {
            "collaborator": {
                "agency": "Hospital Federal de Bonsucesso", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Universidade Federal do Rio de Janeiro", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}